Acorda Therapeutics (ACOR) 36.14 $ACOR
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Acorda
at Investor's Business Daily - Thu Feb 12, 5:30PM CST
Acorda (ACOR) said it earned 46 cents a share in Q4, topping. Revenue rose 27.3% to $117.9 mil, beating views for $110.8 mil. Shares fell 0.7% to 36.65.
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:40AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics ups revenues 27% in Q4
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:59AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
ACOR: 36.14 (-0.51)
Acorda beats Street 4Q forecasts
Automated Insights - Thu Feb 12, 5:42AM CST
ARDSLEY, N.Y. (AP) _ Acorda Therapeutics Inc. (ACOR) on Thursday reported fourth-quarter earnings of $331,000.
ACOR: 36.14 (-0.51)
Acorda Therapeutics EPS of $0.01
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 5:16AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Thu Feb 12, 5:01AM CST
--Full Year AMPYRA 2015 Net Revenue Guidance of $405-$420 Million
ACOR: 36.14 (-0.51)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
3 Big-Volume Stocks to Trade for Breakouts: First Solar and More
at The Street - Wed Feb 11, 1:07PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
FSLR: 48.84 (-0.58), SLAB: 49.26 (-0.27), ACOR: 36.14 (-0.51)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 285.37 (+3.71), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed Feb 11, 8:59AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Tumbles: Stock Goes Down 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:50AM CST
Acorda Therapeutics' shares fell nearly 10% continuing the recent downtrend
ACOR: 36.14 (-0.51), AFFX: 11.45 (+0.02)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
LGCY: 13.35 (+0.51), GEOS: 19.15 (+0.02), MCEP: 6.29 (+0.12), MGPI: 14.00 (-0.39), ACOR: 36.14 (-0.51), CUTR: 11.94 (-0.21), GTLS: 32.02 (+1.27), ENT: 13.56 (+0.29), CENX: 23.10 (-0.17), FSC: 7.23 (+0.12), NILE: 29.02 (+0.07), SOHU: 53.96 (+2.74), LINE: 12.94 (+0.40)
DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:30PM CST
DaVita Healthcare Partners Inc. (DVA) is set to report fourth-quarter and full-year 2014 earnings results on Feb 12, 2015.
ACT: 285.37 (+3.71), LPNT: 69.04 (-0.06), DVA: 73.10 (-3.29), ACOR: 36.14 (-0.51)
Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:40AM CST
Hospira Inc. (HSP) is set to report fourth-quarter 2014 results on Feb 12 before the market opens.
ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51), HSP: 87.35 (unch)
Why Earnings Season Could Be Great for Acorda Therapeutics (ACOR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:55AM CST
Acorda Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
ACOR: 36.14 (-0.51)
Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 2:20PM CST
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release its fourth-quarter 2014 financial results before the opening bell on Feb 10, 2015.
ACT: 285.37 (+3.71), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:50PM CST
Avalanche Biotechnologies (AAVL) is expected to report fourth-quarter 2014 results on Feb 11.
ACT: 285.37 (+3.71), AAVL: 36.29 (+0.01), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:30PM CST
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter 2014 results before the opening bell on Feb 11.
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Acorda
at Investor's Business Daily - Thu Feb 12, 5:30PM CST
Acorda (ACOR) said it earned 46 cents a share in Q4, topping. Revenue rose 27.3% to $117.9 mil, beating views for $110.8 mil. Shares fell 0.7% to 36.65.
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:40AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics ups revenues 27% in Q4
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:59AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
ACOR: 36.14 (-0.51)
Acorda beats Street 4Q forecasts
Automated Insights - Thu Feb 12, 5:42AM CST
ARDSLEY, N.Y. (AP) _ Acorda Therapeutics Inc. (ACOR) on Thursday reported fourth-quarter earnings of $331,000.
ACOR: 36.14 (-0.51)
Acorda Therapeutics EPS of $0.01
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 5:16AM CST
ACOR: 36.14 (-0.51)
Acorda Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Thu Feb 12, 5:01AM CST
--Full Year AMPYRA 2015 Net Revenue Guidance of $405-$420 Million
ACOR: 36.14 (-0.51)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
3 Big-Volume Stocks to Trade for Breakouts: First Solar and More
at The Street - Wed Feb 11, 1:07PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
FSLR: 48.84 (-0.58), SLAB: 49.26 (-0.27), ACOR: 36.14 (-0.51)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 285.37 (+3.71), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today
at The Street - Wed Feb 11, 8:59AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACOR: 36.14 (-0.51)
Acorda Therapeutics (ACOR) Tumbles: Stock Goes Down 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 7:50AM CST
Acorda Therapeutics' shares fell nearly 10% continuing the recent downtrend
ACOR: 36.14 (-0.51), AFFX: 11.45 (+0.02)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
LGCY: 13.35 (+0.51), GEOS: 19.15 (+0.02), MCEP: 6.29 (+0.12), MGPI: 14.00 (-0.39), ACOR: 36.14 (-0.51), CUTR: 11.94 (-0.21), GTLS: 32.02 (+1.27), ENT: 13.56 (+0.29), CENX: 23.10 (-0.17), FSC: 7.23 (+0.12), NILE: 29.02 (+0.07), SOHU: 53.96 (+2.74), LINE: 12.94 (+0.40)
DaVita Healthcare (DVA): What's in Store for Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:30PM CST
DaVita Healthcare Partners Inc. (DVA) is set to report fourth-quarter and full-year 2014 earnings results on Feb 12, 2015.
ACT: 285.37 (+3.71), LPNT: 69.04 (-0.06), DVA: 73.10 (-3.29), ACOR: 36.14 (-0.51)
Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:40AM CST
Hospira Inc. (HSP) is set to report fourth-quarter 2014 results on Feb 12 before the market opens.
ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51), HSP: 87.35 (unch)
Why Earnings Season Could Be Great for Acorda Therapeutics (ACOR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:55AM CST
Acorda Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
ACOR: 36.14 (-0.51)
Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 2:20PM CST
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release its fourth-quarter 2014 financial results before the opening bell on Feb 10, 2015.
ACT: 285.37 (+3.71), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:50PM CST
Avalanche Biotechnologies (AAVL) is expected to report fourth-quarter 2014 results on Feb 11.
ACT: 285.37 (+3.71), AAVL: 36.29 (+0.01), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:30PM CST
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter 2014 results before the opening bell on Feb 11.
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51)
